Decreased Coagulability Has No Clinically Relevant Effect on Atherogenesis
Observations in Individuals With a Hereditary Bleeding Tendency

A. Šrámek, MD; J.H.C. Reiber, PhD; W.B.J. Gerrits, MD; F.R. Rosendaal, MD

Background—Hemostasis affects ischemic cardiovascular disease through its role in formation of occluding arterial thrombi. Several studies suggest that hemostasis also might play a role in atherogenesis. We investigated whether individuals with an inherited bleeding tendency are protected against development of atherosclerosis.

Methods and Results—A total of 76 individuals with an inherited bleeding tendency (hemophilia and von Willebrand disease) and 142 healthy controls were included in the present study. Early atherosclerotic vessel-wall changes were quantified by measurement of intima-media thickness in the carotid and femoral arteries by B-mode ultrasonography. To validate intima-media thickness measurements, measurements also were performed in 77 individuals with clinically proven atherosclerosis and in 34 healthy, age-matched controls. A large difference in intima-media thickness was found between individuals with proven atherosclerosis and healthy controls, in particular for the femoral artery (difference for carotid artery, 0.16 mm; femoral artery, 0.53 mm). Comparison between patients with a bleeding tendency and healthy controls showed only minimally reduced intima-media in femoral artery in individuals with a bleeding tendency (adjusted difference, $-0.078$ mm; 95% CI, $-0.17$ to 0.018 mm). Subgroup analysis revealed that in subjects with moderate to severe hemophilia, vessel walls were thinnest (adjusted difference, $-0.10$ mm; 95% CI, $-0.27$ to 0.061 mm).

Conclusions—Hypocoagulability caused by hemophilia or von Willebrand disease has at most a limited effect on atherogenesis. (Circulation. 2001;104:762-767.)

Key Words: atherosclerosis • coagulation • carotid arteries • femoral arteries • ultrasonics

Results of studies concerning the role of hemostasis in ischemic cardiovascular disease indicate that hypercoagulability increases risk of ischemic cardiovascular disease, whereas hypocoagulability decreases that risk. In many studies, high fibrinogen levels proved to be a risk factor for myocardial infarction and stroke.1–6 Results for other clotting-factor levels, such as factor VII, are less consistent. In these studies, clotting-factor levels were in the normal or subnormal range. Patients with a hereditary deficiency of clotting factors VIII and IX (hemophilia A and B, respectively) have considerable protection against myocardial infarctions.7,8 Furthermore, increased risk of myocardial infarctions was found among carriers of a common prothrombin variant (20210 G to A) that is associated with increased prothrombin levels.9,10 Overall results of these studies indicate that coagulability plays a role in ischemic heart disease, particularly when extremes of coagulability are considered.

Myocardial infarction is the result of 2 processes: slow and chronic development of an atherosclerotic plaque and acute formation of an occluding thrombus at the site of the plaque.11,12 Obviously, hemostasis plays an important role in formation of occluding arterial thrombi. However, results of a number of studies suggest that coagulability also might play a role in atherogenesis. Among patients who suffer from severe peripheral arterial disease, hereditary thrombophilia (caused by protein S deficiency) was more prevalent than in the general population.13 Furthermore, experimental animal studies showed that pigs with complete deficiency of von Willebrand factor were protected against spontaneous development of atherosclerotic plaques.14,15

In the present study, we examined whether hypocoagulability protects against development of atherosclerotic plaques. Early atherosclerotic vessel wall changes were quantified by measuring intima-media thickness in superficial arteries by ultrasonography. Measurements were performed in patients with a hereditary bleeding tendency caused by a clotting-factor deficiency and in healthy controls for comparison. Individuals with a bleeding tendency were patients with hemophilia A or B or who suffered from mild von Willebrand disease. Because hemophiliacs are almost exclusively men,
the present study was restricted to men. Established risk factors of atherogenesis were determined to adjust for differences among groups.

**Methods**

**Study Design**
To validate the methodology, measurements were performed in 77 men who had undergone coronary bypass surgery and in 34 healthy, age-matched men. To determine the role of hypocoagulability in atherogenesis, 76 men with congenital bleeding tendency caused by a deficiency of clotting factors VIII or IX or von Willebrand factor were included. All male patients ≥30 years of age who were treated in the 2 participating centers (Leiden and Den Haag) were eligible and asked to participate. The group consisted of 17 patients with heterozygous von Willebrand disease (mean factor VIII antigen, 45 IU/dL; range, 18 to 97 IU/dL; mean von Willebrand factor antigen, 36 IU/dL; range, 12 to 65 IU/dL) and 34 with mild (>5 IU/dL), 5 with moderate (1 to 5 IU/dL), and 20 with severe (<1 IU/dL) hemophilia (52 with hemophilia A and 7 with hemophilia B). For comparison, 108 individuals were included who had received temporarily prophylactic anticoagulant treatment because of an orthopedic condition such as surgery or fractures. The 34 healthy individuals from the validation study were added, which resulted in a total of 142 healthy male controls. At the time of study, none of the controls was exposed to risk factors for patients with a bleeding tendency who used antihypertensive or cholesterol-lowering drugs. Multivariate regression analysis was used to correct for differences in exposure to established risk factors.

**Measurement of Risk Factors**

Information about use of medication, smoking habits, and presence of cardiovascular disease (myocardial infarction and stroke) before the age of 65 years for first-degree relatives was obtained by use of a standardized questionnaire. Smoking was categorized as number of pack-years an individual had smoked. Body-fat distribution was determined by measurement of waist-to-hip ratio. For each subject, blood pressure was measured 3 times by use of a Hawksley random-zero mercury sphygmomanometer while the subject was in a supine position and after ≥20 minutes of rest. From each individual, we drew fasting blood samples (serum and plasma). Fractions for VLDL, LDL, and HDL determinations were obtained by ultracentrifugation of serum samples. Total serum cholesterol, HDL, LDL, VLDL, and triglyceride concentrations were determined by use of an enzymatic colorimetric method.

**Statistical Analysis**

Vessel-wall thickness of patients and controls was compared by Student’s $t$ test for continuous variables and by $\chi^2$ test for discrete variables, after log-transformation when appropriate. Association of all determinants studied with intima-media thickness was quantified by linear regression. For univariate regression analysis, including blood pressure, we excluded 27 individuals who used antihypertensive drugs; 7 individuals from the regression analysis of lipids were excluded because they used lipid-lowering drugs. Multivariate regression analysis was used to correct for differences in exposure to established risk factors.

**Results**

Patients with coronary bypasses had substantially thicker vessel walls both in the carotid and femoral arteries than healthy, age-matched controls (Figure 2). For the carotid artery, mean difference was 0.16 mm; for the femoral artery, 0.53 mm.

Table 1 shows general characteristics and presence of various risk factors for patients with a bleeding tendency and healthy controls. Mean age of patients was 49 years (range, 31 to 84) and was similar to mean age of controls (mean, 52 years; range, 30 to 76). Exposure to risk factors for atherosclerosis was similar. Percentage of persons with a bleeding tendency who used antihypertensive or cholesterol-lowering drugs (16% and 5%, respectively) was slightly higher than in controls (11% and 2%, respectively). Frequency of hypertension (either drug-treated or high blood pressure) was similar for patients and controls (18% versus 17%, respectively).
For the intima-media thickness in the carotid artery, we observed no difference between healthy controls and patients with a bleeding tendency (Figure 3). Figure 4 shows results for the femoral artery. Mean intima-media was slightly lower for patients with a bleeding tendency; this effect appeared restricted to those with hemophilia (mean difference after logarithmic transformation, 0.11 mm; 95% CI, 0.0028 to 0.22).

In univariate linear regression analysis, most of the established risk factors for atherosclerosis showed a clear relation to intima-media thickness in both arteries (Table 2). Except for HDL, variables showed a more-pronounced effect on thickness in the femoral artery than in the carotid artery. This applied particularly for smoking (coefficient, 0.022 versus 0.068), total cholesterol (coefficient, 0.035 versus 0.11), LDL (coefficient, 0.035 versus 0.14), and presence of hypercholesterolemia (coefficient, 0.070 versus 0.23). Univariate regression analysis of intima-media thickness between controls and individuals with a clotting disorder showed results similar to those shown in Figures 3 and 4: no difference in intima-media thickness of the carotid artery but a slightly thinner femoral intima-media in individuals with a bleeding tendency (−0.091 mm; 95% CI, −0.20 to 0.022 mm), particularly in those with hemophilia (−0.11; 95% CI, −0.23 to 0.016 mm).

Adjustment for established risk factors attenuated differences between controls and patients, but intima-media remained thinner among patients with a coagulation disorder compared with controls (Table 3). This occurrence was true especially in the comparison between patients suffering from moderate to severe hemophilia and controls (adjusted difference, −0.10 mm; 95% CI, −0.27 to 0.061).

**Discussion**

In the present study, we examined whether hypocoagulability results in less atherosclerotic vessel wall changes than normal coagulation. As a model for hypocoagulability, we selected patients suffering from a hereditary deficiency of clotting factor VIII or IX or von Willebrand factor. We observed no clinically relevant effect of decreased coagulability on atherogenesis.

We used B-mode ultrasonography to quantify early atherosclerotic vessel wall changes. In a recent study, we showed that the ultrasound technique used in the present study is accurate and reliable for determination of intima-media thickness in the carotid and femoral arteries.16 Numerous studies found a clear relation between intima-media thickness in the carotid artery and most of the established risk factors, even in

---

**TABLE 1. General Characteristics of Patients With a Clotting Disorder and Healthy Individuals**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Bleeding Tendency (n=76)</th>
<th>Healthy Controls (n=142)</th>
<th>95% CI of Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, y</td>
<td>48.8</td>
<td>51.5</td>
<td>−6.2–0.7</td>
</tr>
<tr>
<td>Smoking, pack-y</td>
<td>16.12</td>
<td>13.47</td>
<td>−1.5–3.2*</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.97</td>
<td>0.97</td>
<td>−0.017–0.015</td>
</tr>
<tr>
<td>Blood pressure, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>117.9</td>
<td>119.0</td>
<td>−3.0–1.0*</td>
</tr>
<tr>
<td>Diastolic</td>
<td>76.6</td>
<td>77.0</td>
<td>−3.37–2.61</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.2</td>
<td>5.4</td>
<td>−0.4–0.2</td>
</tr>
<tr>
<td>VLDL, mmol/L</td>
<td>0.90</td>
<td>0.89</td>
<td>−1.12–3.08*</td>
</tr>
<tr>
<td>LDL, mmol/L</td>
<td>3.3</td>
<td>3.3</td>
<td>−0.2–0.2</td>
</tr>
<tr>
<td>HDL, mmol/L</td>
<td>0.94</td>
<td>0.98</td>
<td>−0.12–0.045</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.2</td>
<td>1.1</td>
<td>−0.20–0.25*</td>
</tr>
<tr>
<td>Positive family history, %</td>
<td>19 (25)</td>
<td>30 (21)</td>
<td>−8–16</td>
</tr>
<tr>
<td>Cholesterol-lowering drugs, %</td>
<td>4 (5)</td>
<td>3 (2)</td>
<td>−2–8</td>
</tr>
<tr>
<td>Antihypertension drugs, %</td>
<td>12 (16)</td>
<td>15 (11)</td>
<td>−4–15</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>14 (18)</td>
<td>24 (17)</td>
<td>−9–12</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>3 (4)</td>
<td>2 (1)</td>
<td>−2–7</td>
</tr>
</tbody>
</table>

Hypertension was defined as systolic blood pressure ≥160 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertension drugs.

*After logarithmic transformation.

---

**Figure 3.** Visual comparison of mean intima-media thickness in carotid artery between healthy individuals and subgroups of individuals with a bleeding tendency. Mean and 95% confidence intervals of the intima-media thickness (in mm) are indicated by , VWD indicates von Willebrand disease.
young individuals\textsuperscript{,19–22} Intima-media thickness in the carotid and femoral arteries is a good indicator of presence of atherosclerosis in coronary and other peripheral arteries.\textsuperscript{23,24} We also found a clear effect of established risk factors on intima-media thickness. Furthermore, we found a large difference in intima-media thickness between patients with clinically proven coronary atherosclerosis and healthy controls.

Numerous studies have been performed about the role of coagulation and clotting factor levels in ischemic cardiovascular disease. In particular, fibrinogen emerged as a risk factor from these studies.\textsuperscript{1–6,25} However, in these studies, clinical end points of cardiovascular disease such as myocardial infarction or stroke were used. Therefore, these studies do not clarify whether coagulation plays a role only in arterial thrombosis or also in atherogenesis. Several studies used carotid intima-media thickness measurements as a surrogate end point of ischemic cardiovascular disease. Results of these studies show no consistent results with respect to association of clotting factor levels with early atherosclerotic changes.\textsuperscript{19,26–28} A possible explanation for this inconsistency is that clotting-factor levels in individuals studied were mainly in the normal to subnormal range. In the present study, we maximized contrast by including patients with hereditary low clotting-factor levels. Because patients were selected on the basis of a genetic trait with high penetrance, selection and confounding are unlikely.

Our results suggest that highly decreased clotting-factor levels may have a small protective effect against atherosclerosis in the femoral artery and no effect in the carotid artery. Previous studies have suggested that different risk factor patterns exist for the carotid and femoral arteries.\textsuperscript{29,30} This variance might be caused by different hemodynamic conditions within these arteries, such as differences in shear stress of the wall and other factors.\textsuperscript{31} Another, perhaps more

### Table 2. Univariate Regression Analysis of Intima-Media Thickness in Carotid and Femoral Arteries

<table>
<thead>
<tr>
<th>Variables</th>
<th>Carotid</th>
<th>Femoral</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coefficient 95% CI</td>
<td>Coefficient 95% CI</td>
</tr>
<tr>
<td>Age (10 y)</td>
<td>0.10 0.087–0.12</td>
<td>0.16 0.12–0.19</td>
</tr>
<tr>
<td>Smoking (10 pack-y)</td>
<td>0.022 0.0071–0.039</td>
<td>0.068 0.035–0.10</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>1.05 0.63–1.48</td>
<td>1.60 0.67–2.51</td>
</tr>
<tr>
<td>Blood pressure (10 mm Hg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>0.046 0.033–0.060</td>
<td>0.085 0.055–0.11</td>
</tr>
<tr>
<td>Diastolic</td>
<td>0.038 0.014–0.061</td>
<td>0.092 0.042–0.14</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>0.035 0.011–0.059</td>
<td>0.11 0.067–0.16</td>
</tr>
<tr>
<td>VLDL (mmol/L)</td>
<td>0.065 0.015–0.12</td>
<td>0.13 0.026–0.23</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>0.035 0.0039–0.065</td>
<td>0.14 0.075–0.20</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>−0.057 −0.15–0.033</td>
<td>0.018 −0.17–0.20</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>0.036 0.0080–0.059</td>
<td>0.070 0.018–0.12</td>
</tr>
<tr>
<td>Positive family history</td>
<td>0.054 −0.0064–0.12</td>
<td>0.11 −0.016–0.24</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.20 0.13–0.26</td>
<td>0.28 0.14–0.42</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>0.070 0.015–0.13</td>
<td>0.23 0.12–0.35</td>
</tr>
<tr>
<td>All with bleeding tendency</td>
<td>−0.0093 −0.063–0.044</td>
<td>−0.091 −0.20–0.022</td>
</tr>
<tr>
<td>Hemophilia</td>
<td>−0.013 −0.073–0.046</td>
<td>−0.11 −0.23–0.016</td>
</tr>
<tr>
<td>Moderate to severe hemophilia</td>
<td>0.0060 −0.078–0.90</td>
<td>−0.097 −0.28–0.084</td>
</tr>
<tr>
<td>Mild hemophilia and VWD</td>
<td>−0.017 −0.077–0.043</td>
<td>−0.088 −0.22–0.043</td>
</tr>
<tr>
<td>VWD</td>
<td>0.0043 −0.089–0.098</td>
<td>−0.033 −0.25–0.18</td>
</tr>
</tbody>
</table>

VWD indicates von Willebrand disease. Hypertension was defined as systolic blood pressure ≥160 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertension drugs. Hypercholesterolemia was defined as total cholesterol ≥6 or use of cholesterol-lowering drugs. Regression coefficient determined for subgroups with a bleeding tendency indicates difference in intima-media thickness (mm) between subgroups and controls (ie, intima-media thickness of subgroup minus intima-media thickness of controls).
plausible, explanation is that measurements in the femoral artery are more sensitive than those in the carotid artery for detection of early atherosclerotic changes. In the comparison between patients with proven coronary atherosclerosis and healthy controls, we found a larger difference in intima-media thickness in the femoral artery than in the carotid artery. This finding suggests that minor changes are detected better in the femoral than carotid artery.

Our results indicate minor effects on atherosclerosis in individuals with extreme hypocoagulability. In a recently published study, presence of advanced atherosclerotic lesions in the carotid artery between patients suffering from hemophilia A and von Willebrand disease were compared with healthy controls. In a recently published study, presence of advanced atherosclerotic lesions in the carotid artery between patients suffering from hemophilia A and von Willebrand disease were compared with healthy controls. In that study, the selection procedure and a general characteristic of the study groups (ie, age) were not documented. Furthermore, only crude data were presented and no adjustments were performed. In experimental animal studies with pigs, protection against atherosclerosis was found in pigs with severe von Willebrand disease, whereas no protection was found in pigs suffering from the mild type of the disease. These results are not in disagreement with our results, because we included only subjects with mild von Willebrand disease (albeit in only a small number of patients).

We studied hereditary deficiencies of clotting factor VIII and IX and von Willebrand factor as a model for hypocoagulability of blood. Deficiencies of these clotting factor levels will result in less formation of thrombin and fibrin (impaired secondary hemostasis) or less platelet aggregation (impaired primary hemostasis). The present model is valid only for the hypotheses in which incorporation of mural thrombi in the vessel wall, mitogen, and other atherosclerotic effects of an increased thrombin and fibrin production are a part of the pathway to atherosclerosis. Some studies suggest that fibrinogen also might have an effect on atherogenesis through its effect on the viscosity of blood. In recent studies, viscosity of blood emerged as an important risk factor for atherosclerotic disease.

In the present study, patients with a bleeding tendency were treated temporarily to correct the clotting disorder during hemorrhages. Some patients received prophylactic treatment to avoid hemorrhages. During periods of prophylaxis and treatment of hemorrhages, the coagulation levels of these patients were increased. A study concerning treatment of hemophilia in the Netherlands showed that ~50% of patients who suffered from severe hemophilia (in particular, younger individuals) receive prophylactic treatment. Prophylactic dosage level is determined so that mean clotting-factor VIII or IX level will be increased by 0.05 to 0.1 IU/mL. Thus, during prophylactic treatment, severity of hemophilia is “converted” from severe to mild. Patients with mild hemophilia usually receive no prophylactic treatment. During bleedings, treatment is aimed at a higher increase in clotting factors. However, treatment in these cases is given only for a period of several days. The same study showed that patients with moderate or severe hemophilia experience a bleeding episode every 3 to 4 weeks, whereas those with mild hemophilia rarely bleed spontaneously. Therefore, treatment has only a limited effect on overall coagulability. Even in case of prophylactic treatment, a high contrast remains in lifetime coagulability between individuals with a severe bleeding disorder and individuals with normal coagulation.

In conclusion, results of the present study suggest a minimal protective effect of extreme hypocoagulability on atherogenesis. Our results indicate that the protection against myocardial infarctions that has been reported in hemophilia patients probably is primarily caused by a decreased tendency to form occluding arterial thrombi. Because we compared early atherosclerotic changes between individuals with a high contrast in coagulability, the protective effect is negligible in individuals with coagulation in the normal or subnormal range.

**Acknowledgments**

The present study was funded by the Netherlands Heart Foundation (No. 93.110). We express our gratitude to all individuals who participated in this study. We thank M. Horstmansion for secretarial and administrative support.
References

Decreased Coagulability Has No Clinically Relevant Effect on Atherogenesis: Observations in Individuals With a Hereditary Bleeding Tendency
A. Srámek, J.H.C. Reiber, W.B.J. Gerrits and F.R. Rosendaal

Circulation. 2001;104:762-767
doi: 10.1161/hc3501.094232
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/104/7/762

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/